Clinical study for PET microdose method by oral dose of [11C]Telmisartan in healthy volunteers

Clinical study for PET microdose method by oral dose of [11C]Telmisartan in healthy volunteers - Pharmacokinetics of [11C]Telmisartan by oral dose in healthy volunteers (TEL-2)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004990

Enrollment

Registered

2011-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy male subjects

Interventions

Oral administration of [11C]Telmisartan.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Normal subjects with body weight >= 50kg and <85kg, and body mass index >= 17.6 and <26.4.

Exclusion criteria

Exclusion criteria: 1. Renal artery stenosis, bilaterally or unilaterally after nephrectomy 2. Hyperkalemia 3. Liver or renal dysfunction 4. Cerebrovascular disorders 5. Hypotension 6. Severe bradycardia, or WPW or LGL syndrome by ECG 7. Medication or dietary supplement including St. John's wort within 7 days prior to PET study

Design outcomes

Primary

Measure	Time frame
Plasma concentration time course and hepatobiliary pharmacokinetics of [11C]telmisartan.	—

Countries

Japan

Contacts

Public ContactMichio Senda

Foundation for Biomedical Research and Innovation Division of Molecular Imaging, Institute of Biomedical Research and Innovation

078(304)5212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026